In this event, Prof Fiona Ducotterd and Prof Paul Brennan shared the latest work taking place at the UK’s specially-created Drug Discovery Alliance.
This initiative brings together world-leading dementia scientists from the Universities of Oxford, Cambridge and University College London.
Each institution houses dedicated biology and chemistry teams to evaluate promising new drug targets. Together, the Drug Discovery Institutes are exploring a wide range of disease mechanisms spanning the full spectrum of dementias.
Watch back to hear from the experts who are working to find the next possible treatment for dementia.
Professor Paul Brennan is the Chief Scientific Officer of the Oxford Drug Discovery Institute (ODDI) at the University of Oxford. He joined the ODDI as the Head of Chemistry in 2015. As a highly accomplished medicinal chemist with particular expertise in early drug discovery, he has been instrumental in developing and leading the Institute’s diverse portfolio of drug discovery projects.
Prof Fiona Ducotterd is Chief Scientific Officer at the Alzheimer’s Research UK Drug Discovery Institute at UCL in London where she leads a team of multidisciplinary scientists discovering new medicines for neurodegenerative diseases including Alzheimer’s diseaseFiona is also a mentor and coach to early career scientists and other professionals, particularly those that are under-represented in the industry and a mum to 1 year old Isla and fur baby, Yuna.